Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Yabing Guo"'
Autor:
Li Xu, Jinzhang Chen, Chang Liu, Xiaoling Song, Yanqiao Zhang, Haitao Zhao, Sheng Yan, Weidong Jia, Zheng Wu, Yabing Guo, Jiayin Yang, Wei Gong, Yue Ma, Xiaobo Yang, Zhenzhen Gao, Nu Zhang, Xin Zheng, Mengyu Li, Dan Su, Minshan Chen
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Background Lenvatinib is widely used in treatment of unresectable hepatocellular carcinoma (uHCC), but the benefit of its combination with immunotherapy needs to be verified. This study evaluated the efficacy and safety of tislelizumab plus
Externí odkaz:
https://doaj.org/article/c3ae2efaf43843d5896283b1c2eb7e47
Autor:
Kunyuan Wang, Hao Cui, Yun Zhu, Xiaoyun Hu, Chang Hong, Yabing Guo, Lingyao An, Qi Zhang, Li Liu
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Artificial intelligence (AI)-assisted clinical trial screening is a promising prospect, although previous matching systems were developed in English, and relevant studies have only been conducted in Western countries. Therefore, w
Externí odkaz:
https://doaj.org/article/ef7954dba0904df19fd9bee7dff8ce98
Autor:
Jian Zhou, Huichuan Sun, Zheng Wang, Wenming Cong, Mengsu Zeng, Weiping Zhou, Ping Bie, Lianxin Liu, Tianfu Wen, Ming Kuang, Guohong Han, ZhiPing Yan, Maoqiang Wang, Ruibao Liu, Ligong Lu, Zhenggang Ren, ZhaoChong Zeng, Ping Liang, Changhong Liang, Min Chen, Fuhua Yan, Wenping Wang, Jinlin Hou, Yuan Ji, Jingping Yun, Xueli Bai, Dingfang Cai, Weixia Chen, Yongjun Chen, Wenwu Cheng, Shuqun Cheng, Chaoliu Dai, Wenzhi Guo, Yabing Guo, Baojin Hua, Xiaowu Huang, Weidong Jia, Qiu Li, Tao Li, Xun Li, Yaming Li, Yexiong Li, Jun Liang, Changquan Ling, Tianshu Liu, Xiufeng Liu, Shichun Lu, Guoyue Lv, Yilei Mao, Zhiqiang Meng, Tao Peng, Weixin Ren, Hongcheng Shi, Guoming Shi, Ming Shi, Tianqiang Song, Kaishan Tao, Jianhua Wang, Kui Wang, Lu Wang, Wentao Wang, Xiaoying Wang, Zhiming Wang, Bangde Xiang, Baocai Xing, Jianming Xu, Jiamei Yang, Jianyong Yang, Yefa Yang, Yunke Yang, Shenglong Ye, Zhenyu Yin, Yong Zeng, Bixiang Zhang, Boheng Zhang, Leida Zhang, Shuijun Zhang, Ti Zhang, Yanqiao Zhang, Ming Zhao, Yongfu Zhao, Honggang Zheng, Ledu Zhou, Jiye Zhu, Kangshun Zhu, Rong Liu, Yinghong Shi, Yongsheng Xiao, Lan Zhang, Chun Yang, Zhifeng Wu, Zhi Dai, Minshan Chen, Jianqiang Cai, Weilin Wang, Xiujun Cai, Qiang Li, Feng Shen, Shukui Qin, Gaojun Teng, Jiahong Dong, Jia Fan
Publikováno v:
Liver Cancer (2023)
Background: Primary liver cancer, around 75%–85% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chin
Externí odkaz:
https://doaj.org/article/ab60b55b31574ba8a11cb8dd36227daf
Autor:
Guoliang Shao, Yuxian Bai, Xianglin Yuan, Xiaomin Chen, Shanzhi Gu, Kangsheng Gu, Chunhong Hu, Houjie Liang, Yabing Guo, Jufeng Wang, Chia-Jui Yen, Victor Ho-Fun Lee, Chunxiao Wang, Ryan C. Widau, Wanli Zhang, Junjun Liu, Qiang Zhang, Shukui Qin
Publikováno v:
EClinicalMedicine, Vol 54, Iss , Pp 101679- (2022)
Summary: Background: In the global REACH-2 study, ramucirumab significantly improved overall survival (OS) compared with placebo in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP). REACH-2 China study aimed
Externí odkaz:
https://doaj.org/article/e806fe3c322947ce9fe7c571dbf725cc
Autor:
Qi Li, Mengran Cao, Guosheng Yuan, Xiao Cheng, Mengya Zang, Ming Chen, Xiaoyun Hu, Jing Huang, Rong Li, Yabing Guo, Jian Ruan, Jinzhang Chen
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundCombining an antiangiogenic agent with an anti-PD-1 agent is a promising strategy for unresectable hepatocellular carcinoma (HCC).AimsTo explore the effectiveness and tolerability of lenvatinib plus camrelizumab vs. lenvatinib monotherapy a
Externí odkaz:
https://doaj.org/article/c6a2dd20c06b462f8a052f55f10684b3
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/d4543361ab4044d385ec1e9899346b66
Publikováno v:
ACS Omega, Vol 4, Iss 20, Pp 18574-18581 (2019)
Externí odkaz:
https://doaj.org/article/4429dae12b2449f7bff57b9bf7d5df2a
Autor:
Hongkun Qin, Yanping Gui, Rong Ma, Heng Zhang, Yabing Guo, Yuting Ye, Jia Li, Li Zhao, Yajing Wang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
MicroRNAs are a group of endogenous small non-coding RNAs commonly dysregulated in tumorigenesis, including glioblastoma (GBM), the most malignant brain tumor with rapid proliferation, diffuse invasion, and therapeutic resistance. Accumulating eviden
Externí odkaz:
https://doaj.org/article/bc0a9f9a8d5a40359be42741d9577a49
Autor:
Guosheng Yuan, Yangda Song, Qi Li, Xiaoyun Hu, Mengya Zang, Wencong Dai, Xiao Cheng, Wei Huang, Wenxuan Yu, Mian Chen, Yabing Guo, Qifan Zhang, Jinzhang Chen
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
BackgroundThere is no study accessible now assessing the prognostic aspect of radiomics for anti-PD-1 therapy for patients with HCC.AimThe aim of this study was to develop and validate a radiomics nomogram by incorporating the pretreatment contrast-e
Externí odkaz:
https://doaj.org/article/6ad1be55b4cc4f73ab0db7bd566f06b0
Autor:
Shukui Qin, Stephen Lam Chan, Wattana Sukeepaisarnjaroen, Guohong Han, Su Pin Choo, Virote Sriuranpong, Hongming Pan, Thomas Yau, Yabing Guo, Minshan Chen, Zhenggang Ren, Jianming Xu, Chia-Jui Yen, Zhong-Zhe Lin, Luigi Manenti, Yi Gu, Yongjian Sun, Ralph Tiedt, Lu Hao, Wenjie Song, Tawesak Tanwandee
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Background: The objectives of this phase II study were to determine the clinical activity of the MET tyrosine kinase inhibitor capmatinib (INC280) in patients with MET-dysregulated advanced hepatocellular carcinoma (HCC) and to assess the safety, pha
Externí odkaz:
https://doaj.org/article/ace2bdd311df47e28fcc905ca87b938c